When using an NGS approach to evaluate EGFR status, 37.5% (18/48) of laboratories used a tumour cell threshold of ≥10%, 29.7% (14/48) used ≥5%, and 16.7% (8/48) used a threshold of ≥20% (Figure 2B). The gene discussed is EGFR; the disease is neoplasm.